Suppr超能文献

通过动态体外脂肪分解研究脂质体在肠道中的命运。

Exploring the fate of liposomes in the intestine by dynamic in vitro lipolysis.

机构信息

Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Germany.

出版信息

Int J Pharm. 2012 Nov 1;437(1-2):253-63. doi: 10.1016/j.ijpharm.2012.08.018. Epub 2012 Aug 19.

Abstract

Liposomes are generally well tolerated drug delivery systems with a potential use for the oral route. However, little is known about the fate of liposomes during exposure to the conditions in the gastro-intestinal tract (GIT). To gain a better understanding of liposome stability in the intestine, a dynamic in vitro lipolysis model, which so far has only been used for the in vitro characterisation of other lipid-based drug delivery systems, was applied to different liposomal formulations. Liposome size and phospholipid (PL) digestion were determined as two markers for liposome stability. In addition, the effect of PL degradation on the ability to maintain liposomally incorporated danazol in solution during lipolysis was evaluated in order to address the feasibility of liposomes designed for oral administration. Rate and extend of hydrolysis of PLs mediated by pancreatic enzymes was determined by titration and HPLC. Size of liposomes was determined by dynamic light scattering during incubation in lipolysis medium (LM) and during lipolysis. SPC-based (soy phosphatidylcholine) liposomes were stable in LM, whereas for EPC-3-based (hydrated egg phosphatidylcholine) formulations the formation of aggregates of around 1 μm in diameter was observed over time. After 60 min lipolysis more than 80% of PLs of the SPC-liposomes were digested, but dependent on the liposome concentration only a slight change in size and size distribution could be observed. Although EPC-3 formulations did form aggregates during lipolysis, the lipids exhibited a higher stability compared to SPC and only 30% of the PLs were digested. No direct correlation between liposome integrity assessed by vesicle size and PL digestion was observed. Danazol content in the liposomes was around 5% (mol/mol danazol/total lipid) and hardly any precipitation was detected during the lipolysis assay, despite pronounced lipolytic degradation and change in vesicle size. In conclusion, the tested dynamic in vitro lipolysis model is suitable for the assessment of liposome stability in the intestine. Furthermore, liposomes might be a useful alternative to other lipid based delivery systems for the oral delivery of poorly soluble drugs.

摘要

脂质体是一种普遍耐受性良好的药物递送系统,具有经口服途径给药的潜力。然而,人们对脂质体在胃肠道(GIT)环境中暴露时的命运知之甚少。为了更好地了解脂质体在肠道中的稳定性,应用了一种动态体外脂肪分解模型,该模型迄今为止仅用于其他基于脂质的药物递送系统的体外特性研究,用于不同的脂质体制剂。脂质体大小和磷脂(PL)消化被确定为脂质体稳定性的两个标志物。此外,还评估了 PL 降解对在脂肪分解过程中维持脂质体包封的达那唑在溶液中存在的能力的影响,以解决设计用于口服给药的脂质体的可行性。通过滴定和 HPLC 测定胰腺酶介导的 PL 水解的速率和程度。在脂肪分解介质(LM)孵育期间和脂肪分解过程中,通过动态光散射测定脂质体的大小。基于 SPC(大豆磷脂酰胆碱)的脂质体在 LM 中稳定,而基于 EPC-3(水合卵磷酯酰胆碱)的制剂则随着时间的推移观察到直径约 1μm 的聚集物的形成。脂肪分解 60 分钟后,SPC 脂质体的超过 80%的 PL 被消化,但仅观察到脂质体浓度的轻微变化,大小和分布也发生了变化。尽管 EPC-3 制剂在脂肪分解过程中形成了聚集物,但与 SPC 相比,这些脂质表现出更高的稳定性,只有 30%的 PL 被消化。通过囊泡大小评估的脂质体完整性与 PL 消化之间没有直接的相关性。脂质体中的达那唑含量约为 5%(摩尔/摩尔达那唑/总脂质),尽管脂肪分解降解明显且囊泡大小发生变化,但在脂肪分解测定中几乎未检测到沉淀。总之,所测试的动态体外脂肪分解模型适合评估脂质体在肠道中的稳定性。此外,对于口服递送达那唑等难溶性药物,脂质体可能是其他基于脂质的递送系统的有用替代方案。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验